NIH Funds UAB-Vivo Biosciences Research Team in Vascular Grafts
NIH-National Center for Advancing Translational Sciences (NCATS) has funded a UAB-Vivo biosciences research team for conducting translational research on vascular grafts led by Principal Investigator Yogesh K. Vohra, PhD. This Phase-I award of $192,314 is under the Small Business Technology Transfer (STTR) program. Approximately 1.4 million surgical procedures that require arterial prostheses are performed annually in the US due to peripheral vascular disease and ischemic heart disease; approximately 500,000 of these are coronary artery bypass operations. The current commercially available synthetic grafts have not been found suitable for small vessel (<6 mm) applications, with a <50% patency rate at 12 months. Disadvantages of prosthetic grafts include increased risk of thrombosis, poor tissue response and integration and poor biomechanics of graft, leading to additional interventions. Because there are no acceptable synthetic prostheses for small-diameter blood vessels, there is a huge demand for tissue engineered vascular grafts, especially small diameter vascular grafts for coronary replacement. The overall goal of this new program is the development and evaluation of a novel functionally-graded biohybrid vascular graft for small diameter for coronary bypass applications. Tissue engineered vascular constructs developed to date have been engineered mostly using synthetic and animal-derived biomaterials and require pre-seeding of cells before implantation to overcome the complications of prosthetic vascular grafts. However, these biohybrid systems exhibit many limitations including poor cellular adhesion, inadequate biomechanical and functional properties. The UAB research group has recently demonstrated an in vitro regenerated human endothelium on functionally-layered polymeric scaffolds containing bioactive proteins (Figure below). Moreover, Vivo Biosciences has developed a unique human biomatrix (HuBiogel™) that allows viable tissue constructs by cultivating single or multiple cell types. The research team will combine our functionally-layered graft strategy with this physiological HuBiogel culture technology for fabricating an advanced 3D vascular construct demonstrating enhanced lumen endothelialization and biocompatibility. Our research team includes Dr. Yogesh Vohra (PI, UAB Physics/College of Arts and Sciences) Dr. Vinoy Thomas (UAB MSE/School of Engineering) Dr. Steven Pogwizd (School of Medicine – Cardiovascular Disease)
and Dr. Raj Singh (President -Vivo Biosciences).
In 2007, National Institutes of Health (NIH) funded a Shared Instrumentation Grant entitled “Imaging/Mapping Fourier Transform Infrared Microscope”. PI for this NIH instrumentation grant is Dr. Andrei Stanishevsky of the Department of Physics. This new facility will be utilized by CNMB scientists to characterize biomaterials for applications in implants and tissue engineering.
UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.